cfa-mir-130b: Cfa-mir-130b is a microRNA that has been found to be upregulated in dogs with various heart diseases, including MMVD, PDA, and PS [PMC8542680]. It has been shown to be more accurate than NT-proBNP in discriminating dogs with heart diseases from healthy dogs [PMC8542680]. Cfa-mir-130b is commonly upregulated in different heart diseases, suggesting that it may be related to common physiological or pathological changes induced by these diseases [PMC8542680]. However, the specific target genes and pathways of cfa-mir-130b in heart diseases have not been identified and validated yet [PMC8542680]. In MMVD stage B, cfa-mir-130b showed a strong positive correlation with HR, NT-proBNP, and LA/Ao ratio [PMC8542680]. It also showed higher sensitivity and specificity than NT-proBNP in MMVD stage B, PDA, and PS groups [PMC8542680]. However, cfa-mir-130b was not found to be a reliable biomarker for the entire MMVD group or for advanced stages of the disease (stage C and D) [PMC8542680]. In addition to its role as a biomarker for heart diseases in dogs, cfa-mir-130b has also been implicated in the pathogenesis and inflammatory responses of canine echinococcosis [PMC7480022]. Overall, cfa-mir-130b shows promise as a common biomarker for various heart diseases in dogs but further research is needed to fully understand its target genes and pathways as well as its role in different stages of disease progression.